电针降低非酒精性脂肪性肝炎患者MRI-PDFF肝脏脂肪含量:随机对照预试验
该随机对照预试验将60例NASH患者按1:1分配至假针组或电针组,12周内各接受36次治疗。电针组MRI-PDFF相对肝脏脂肪含量降幅(-33.6%)显著大于假针组(-15.8%)(p=0.022),且更多患者达到MRI-PDFF 30%降幅(53.3% vs 25.9%,p=0.035)。电针还显著降低第16周体重和BMI,安全性良好。
要点
- 12周电针可安全有效降低NASH患者MRI-PDFF肝脏脂肪含量。
- 电针组达MRI-PDFF 30%降幅比例显著高于假针组。
- 电针还降低第16周体重和BMI,但肝硬度无显著变化。
核心结论
- 12周电针能有效且安全地降低非酒精性脂肪性肝炎患者的相对肝脏脂肪含量。
- 仍需进一步多中心随机对照研究验证。
研究设计与样本
- 随机对照预试验,NASH患者按1:1随机分配至假针组或电针组,患者设盲。
- 共纳入60例患者,每组在12周内接受36次治疗,随访至第16周。
- 主要结局为MRI-PDFF测量的相对肝脏脂肪含量变化。
主要发现
- 基线至第12周,电针组MRI-PDFF相对肝脏脂肪含量降幅(-33.6%,分位范围:-52.9%,-22.7%)显著大于假针组(-15.8%,分位范围:-36.1%,-2.7%)(p=0.022)。
- 第12周电针组达到MRI-PDFF 30%降幅的患者比例显著高于假针组(53.3% vs 25.9%,p=0.035)。
- 第16周电针组体重(-3.0 vs +0.1 kg,p=0.034)和BMI(-1.5 vs -0.2 kg/m2,p=0.013)显著降低。
- 除AST(-27.4 vs -16.2 U/L,p=0.015)外,ALT、空腹血糖、胆固醇和甘油三酯组间差异无统计学意义。
- 两组MRE测量的肝硬度均无显著变化,均无严重不良事件。
临床怎么用
- 对于NASH患者,可考虑将12周电针作为降低肝脏脂肪含量的辅助治疗选择。
- 治疗期间可关注体重和BMI的同步改善,但肝硬度改善不明确。
局限性
- 为单中心预试验,样本量60例,结论需多中心大样本随机对照研究进一步验证。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
BACKGROUND: Non-alcoholic steatohepatitis (NASH) had not yet been approved therapy. Electro-acupuncture (EA) has been reported to have potential efficacy. However, high-quality clinical evidence was still lacking. METHODS: NASH patients were randomized and allocated to either sham acupuncture (SA) or EA group in a 1:1 ratio, with the patient blinded. Each patient received 36 sessions of SA or EA treatment over 12 weeks, followed by additional 4 weeks. The primary outcome was the changes in relative liver fat content measured by magnetic resonance imaging proton density fat fraction (MRI-PDFF). RESULTS: A total of 60 patients were enrolled. From baseline to week 12, the reduction of relative liver fat content measured by MRI-PDFF in the EA group (- 33.6%, quantile range: - 52.9%, - 22.7%) was significantly more significant than that in the SA group (- 15.8%, quantile range: - 36.1%, - 2.7%) (p = 0.022). Furthermore, the EA group had more patients who achieved MRI-PDFF to 30% reduction at week 12 (53.3% vs. 25.9%, p = 0.035). EA treatment also significantly reduced body weight (- 3.0 vs. + 0.1 kg, p = 0.034) and BMI (- 1.5 vs. - 0.2 kg/m2, p = 0.013) at week 16. Except for AST (- 27.4 vs. - 16.2 U/L, p = 0.015), other biochemical varieties, including ALT, fasting-glucose, cholesterol, and triglyceride, showed no statistically significant difference. Both groups measured no significant changes in liver stiffness by magnetic resonance elastography (MRE). There were no serious adverse events in either group. CONCLUSIONS: Twelve weeks of EA effectively and safely reduces relative liver fat content in NASH patients. Further multicenter randomized controlled studies are needed. Trial registration Chinese Clinical Trial Registry, ChiCTR2100046617. Registered 23 May 2021, http://www.chictr.org.cn/edit.aspx?pid=127023&htm=4.
引用
- Zhao J, Wang Q, Zhao X, et al. Electro-acupuncture reduced steatosis on MRI-PDFF in patients with non-alcoholic steatohepatitis: a randomized controlled pilot clinical trial. Chin Med. 2023. PMID: 36829229. doi:10.1186/s13020-023-00724-w
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。